Trial Profile

A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvelisib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms FRESCO
Sponsors Infinity Pharmaceuticals; Secura Bio; Verastem Oncology

Most Recent Events

10 Mar 2022 This trial has been discontinued in Italy according to European Clinical Trials Database record.
03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
28 Jul 2017 Status changed to withdrawn prior to enrolment as sponsor is focusing on studies which can enable registration of duvelisib

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com